| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 1.14 [0.88, 1.47] | | < 1 | | 0% | 1 study (1/-) | 15.6 % | NA | not evaluable | | crucial | - |
| progression or deaths (PFS) | 1.68 [1.20, 2.36] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | important | - |
| DCR | 2.02 [1.33, 3.07] | | > 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 0.89 [0.27, 2.92] | | > 1 | | 0% | 1 study (1/-) | 42.4 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| TRAE (any grade) | 0.45 [0.26, 0.76] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.41 [0.24, 0.68] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.95 [0.06, 15.24] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| TRAE leading to discontinuation (any grade) | 0.87 [0.38, 1.95] | | < 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Abdominal pain TRAE (grade 3-4) | 0.47 [0.02, 14.15] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Acute kidney injury TRAE (grade 3-4) | 1.90 [0.06, 56.93] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Adrenal insufficiency TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Anaemia TRAE (grade 3-4) | 0.30 [0.08, 1.14] | | < 1 | | 0% | 1 study (1/-) | 96.1 % | NA | not evaluable | | non important | - |
| Asthenia TRAE (grade 3-4) | 0.47 [0.02, 14.15] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.90 [0.06, 56.93] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Colitis TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Constipation TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Diarrhoea TRAE (grade 3-4) | 9.70 [0.53, 178.83] | | < 1 | | 0% | 1 study (1/-) | 6.5 % | NA | not evaluable | | non important | - |
| Dry skin TRAE (grade 3-4) | 0.47 [0.02, 14.15] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Dyspnoea TRAE (grade 3-4) | 1.90 [0.06, 56.93] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Fatigue TRAE (grade 3-4) | 0.16 [0.01, 3.13] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 0.16 [0.01, 3.13] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 1.90 [0.06, 56.93] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Hypertension TRAE (grade 3-4) | 3.82 [0.17, 85.21] | | < 1 | | 0% | 1 study (1/-) | 20.2 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.90 [0.06, 56.93] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Increase AST TRAE (grade 3-4) | 3.82 [0.17, 85.21] | | < 1 | | 0% | 1 study (1/-) | 20.2 % | NA | not evaluable | | non important | - |
| Increased ALT TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.90 [0.06, 56.93] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.47 [0.02, 14.15] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.16 [0.01, 3.13] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.47 [0.02, 14.15] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.31 [0.03, 3.03] | | < 1 | | 0% | 1 study (1/-) | 84.1 % | NA | not evaluable | | non important | - |
| Nausea TRAE (grade 3-4) | 0.47 [0.02, 14.15] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.87] | | < 1 | | 0% | 1 study (1/-) | 97.9 % | NA | not evaluable | | non important | - |
| Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) | 0.05 [0.00, 0.87] | | < 1 | | 0% | 1 study (1/-) | 97.9 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 0.23 [0.01, 5.24] | | < 1 | | 0% | 1 study (1/-) | 81.7 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Peripheral oedema TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Pneumonia TRAE (grade 3-4) | 1.90 [0.06, 56.93] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 0.95 [0.06, 15.24] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Pruritus TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Pyrexia TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 0.16 [0.01, 3.13] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
| Sepsis TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Skin exfoliation TRAE (grade 3-4) | 0.95 [0.02, 47.96] | | < 1 | | 0% | 1 study (1/-) | 51.1 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.09 [0.01, 1.70] | | < 1 | | 0% | 1 study (1/-) | 94.4 % | NA | not evaluable | | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.47 [0.02, 14.15] | | < 1 | | 0% | 1 study (1/-) | 66.5 % | NA | not evaluable | | non important | - |
| Vomiting TRAE (grade 3-4) | 0.31 [0.03, 3.03] | | < 1 | | 0% | 1 study (1/-) | 84.1 % | NA | not evaluable | | non important | - |
